Missing/wrong data?
Log in to edit
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.
scientific article published on 26 July 2017
Author/s
Work details
Publication date
July 26, 2017
-
-
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.